Abstract:In the era of precision medicine, genetic test results have become increasingly relevant in the care of patients with Parkinson's disease (PD) and their families. While large PD research consortia are performing widespread research genetic testing to accelerate discoveries, debate continues about whether, and to what extent, the results should be returned to patients. Ethically, it is imperative to keep participants informed, especially when findings are potentially actionable. However, research testing may not hold the same standards required from clinical diagnostic laboratories and hold significant psychosocial implications. The absence of universally recognized protocols complicates the establishment of appropriate guidelines. Aiming to develop recommendations on return of research results (RoR) practice within the Global Parkinson's Genetics Program (GP2), we conducted a global survey to gain insight on GP2 members' perceptions, practice, readiness, and needs surrounding RoR. GP2 members (n=191), representing 147 institutions and 60 countries across six continents, completed the survey. Access to clinical genetic testing services was significantly higher in high-income countries compared to low- and middle-income countries (96.6% vs. 58.4%), where funding was predominantly covered by patients themselves. While 92.7% of the respondents agreed that genetic research results should be returned, levels of agreement were higher for clinically relevant results relating to pathogenic or likely pathogenic variants in genes known to cause PD or other neurodegenerative diseases. Less than 10% offered separate clinically-accredited genetic testing before returning genetic research results. 48.7% reported having a specific statement on RoR policy in their ethics consent form, while 53.9% collected data on participants' preferences on RoR prospectively. 24.1% had formal genetic counselling training. Notably, the comfort level in returning incidental genetic findings or returning results to unaffected individuals remains low. Given the differences in resources and training for RoR, as well as ethical and regulatory considerations, tailored approaches are required to ensure equitable access to RoR. Several identified strategies to enhance RoR practices include improving informed consent processes, increasing capacity for genetic counselling including providing counselling toolkits for common genetic variants, broadening access to sustainable clinically-accredited testing, building logistical infrastructure for RoR processes, and continuing public and healthcare education efforts on the important role of genetics in PD.

Genetic Testing Experiences of People Living with Inherited Retinal Degenerations: Results of a Global Survey

Patient experiences and perceived value of genetic testing in inherited retinal diseases: a cross-sectional survey

Genetic Testing of Patients with Inherited Retinal Diseases in the European Countries. An International Survey by the European Vision Institute

A multinational survey of potential participant perspectives on ocular gene therapy

Survey of perspectives of people with inherited retinal diseases on ocular gene therapy in Australia

Perspectives of carriers of X-linked retinal diseases on genetic testing and gene therapy: A global survey

Current Management of Inherited Retinal Degeneration Patients in Europe: Results of a 2-Year Follow-Up Multinational Survey by the European Vision Institute Clinical Research Network - EVICR.net

Streamlined Ophthalmologist-Led Pathway to Diagnosis and Accessibility of Genetics Testing for Patients with Inherited Retinal Dystrophies in Canada

Comparison of The Results of Sponsored Genetic Testing Panels for Inherited Retinal Diseases

Awareness, experiences and perceptions regarding genetic testing and the return of genetic and genomics results in a hypothetical research context among patients in Uganda: a qualitative study

Knowledge of genetic eye diseases and genetic services and attitudes toward genetic testing and gene therapy

Practice Patterns and Challenges in Managing Inherited Retinal Diseases Across Asia-Pacific: A Survey from the APIED Network

Genetic landscape of inherited retinal dystrophies in a Welsh Tertiary Referral Centre

The need for widely available genomic testing in rare eye diseases: an ERN-EYE position statement

Practical guide to genetic screening for inherited eye diseases

Genetic Characterization of 191 Probands with Inherited Retinal Dystrophy by Targeted NGS Analysis

Global Perspectives on Returning Genetic Research Results in Parkinson's Disease

Identifying barriers to genetic testing in subspecialty cardiac care

MAGENTA: a Multinational patient survey assessing the Awareness, perceptions and unmet needs in GENetic Testing and counselling among patients with breAst cancer

Implementing a genetic testing station in a safety net setting for equitable genetic testing and counseling.

Genetic findings of inherited retinal diseases in France